|
業務類別
|
Biotechnology |
|
業務概覽
|
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Itsintegrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
| 公司地址
| 828 Winter Street, Suite 300, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 857 524-2466 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.xiliotx.com |
| 員工數量
| 76 |
| Mr. Christopher Frankenfield |
Chief Financial Officer and Chief Operating Officer |
美元 533.10K |
28/04/2026 |
| Dr. Rene Russo, Pharm.D. |
Director, Chief Executive Officer and President |
美元 643.70K |
28/04/2026 |
| Dr. Katarina Luptakova, M.D. |
Chief Medical Officer |
美元 481.30K |
28/04/2026 |
| Mr. Kevin M. Brennan |
Senior Vice President, Finance and Principal Accounting Officer |
-- |
28/04/2026 |
|
|
| Mr. Robert Ross, M.D. |
Independent Director |
28/04/2026 |
| Ms. Sara M. Bonstein |
Chairman of the Board |
08/01/2026 |
| Dr. Aoife M. Brennan, M.D. |
Independent Director |
28/04/2026 |
| Dr. Rene Russo, Pharm.D. |
Director, Chief Executive Officer and President |
28/04/2026 |
| Dr. Yuan Xu, PhD |
Independent Director |
28/04/2026 |
| Dr. Cheryl R. Blanchard, PhD |
Director |
16/04/2026 |
| Dr. Cheryl R. Blanchard, PhD |
Independent Director |
28/04/2026 |
| Dr. Daniel Curran, M.D. |
Independent Director |
28/04/2026 |
| Dr. Akintunde Bello, PhD |
Independent Director |
28/04/2026 |
| Mr. James Shannon, M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
